H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on EVO stock, giving a Buy rating on April 17.
Douglas Tsao has given his Buy rating due to a combination of factors including Evotec AG’s strong fourth-quarter performance and strategic initiatives aimed at long-term growth. The company reported a notable increase in revenue for the fourth quarter, surpassing expectations and indicating a positive trajectory ahead of its anticipated recovery timeline.
Furthermore, Evotec has implemented a comprehensive recovery strategy, which includes cost-saving measures and a strategic review to enhance its business model. The company’s guidance for 2025 suggests a promising outlook with expected revenue growth and improved EBITDA margins. Additionally, the Just-Evotec Biologics segment is projected to be a key growth driver, supported by strategic partnerships and technological advancements, positioning the company well for future success.
In another report released on April 17, TD Cowen also maintained a Buy rating on the stock with a $7.00 price target.